Assessment of cerebral blood flow in diabetic patients with no clinical history of neurological disease.
We assessed cerebral blood flow in 78 diabetic patients (40 Type 1 and 38 Type 2) with no previous history of central nervous system disease using 99Tcm-hexamethylpropylene amine oxime (99Tcm-HMPAO) single photon emission tomography (SPET) and found areas of severe hypoperfusion in 36% of them. All cerebral anatomical regions showed abnormalities related to hypoperfusion, but they were most frequently seen in the fronto-temporal region, followed by the occipital and parietal regions. 99Tcm-HMPAO SPET has been shown to be able to detect subclinical alterations in blood flow in diabetes, a finding that may account for the high prevalence of cerebrovascular disease seen in these patients. This technique could, therefore, play an important role in future preventative strategies.
Jimenez-Bonilla
J F
JF
Servicio de Medicina Nuclear, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Carril
J M
JM
Quirce
R
R
Gomez-Barquin
R
R
Amado
J A
JA
Gutierrez-Mendiguchia
C
C
D000328:Adult; D000368:Aged; D002560:Cerebrovascular Circulation; D002561:Cerebrovascular Disorders / Q000209:etiology; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000000981:diagnostic imaging* / Q000503:physiopathology*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000000981:diagnostic imaging / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000000981:diagnostic imaging / Q000503:physiopathology; D003925:Diabetic Angiopathies / Q000209:etiology; D003929:Diabetic Neuropathies / Q000209:etiology; D006801:Humans; D008875:Middle Aged; D015609:Organotechnetium Compounds; D010091:Oximes; D019690:Technetium Tc 99m Exametazime; D015899:Tomography, Emission-Computed, Single-Photon
D015609:Organotechnetium Compounds; D010091:Oximes; D019690:Technetium Tc 99m Exametazime